Previous Article | Next Article 
Journal of Clinical Microbiology, October 2001, p. 3808-3808, Vol. 39, No. 10
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3808.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
LETTERS TO THE EDITOR
Foot and Mouth Disease: a Revised Policy Is Required
 |
LETTER |
Foot and mouth disease (FMD) is an economically important
disease of cloven-hoofed animals and is probably the most contagious disease known to humanity. The complexity of the disease includes the
host range of more than 33 domestic and wild cloven-hoofed animals.
Although most of the countries in the European Union and in North
America have controlled the disease by slaughter of infected and
exposed animals, the disease is endemic to many countries of Africa,
Asia, and South America. Regular prophylactic vaccination using an
immunodominant local strain of the virus is therefore practiced
in many countries as a primary control measure. However, vaccinated
animals become seropositive for FMD and cannot be readily distinguished
from infected animals. Also, the virus is able to persist in cattle and
small ruminants irrespective of vaccination status. FMD-free countries
have never used prophylactic vaccination for the disease control;
rather, they have preferred to enforce a strict animal movement and
slaughtering policy. Although this policy has been highly successful in
limiting the extent of outbreaks and eliminating the infection, it is
double edged. Primarily, cessation of vaccination leads to the
animals' having almost no residual immunity, thus making them highly
vulnerable to disease and resulting in the possibility of rapid
dissemination of infection, particularly in densely populated areas. In
fact, Europe's vulnerability has been underlined by the most recent outbreaks in Italy, Greece, and the United Kingdom, which stress the
necessity of revising the policy of FMD-free countries (3, 4,
8).
In the face of the move toward globalization and highly mobile
human populations, each country is facing threats of outbreaks due to
emerging and reemerging infections. The FMD outbreak in the United
Kingdom has been traced to meat imported illegally from West Asia. The
virus can persist outside the host for more than a month and is
dispersed by wind over long distances (60 to 250 km). In addition,
inanimate objects (mechanical carriers) can transmit the virus from one
place to another. Thus, a policy of slaughtering and restricting animal
movement alone may not be the optimal solution to the present scenario
when we consider the costs of implementing such control measures and
the high loss of valuable livestock. Also, the disposal of thousands of
animals per day by incineration or burial poses enormous logistical problems.
This may be the right time to consider vaccination with
recombinant-based vaccines (encoding VP1 or whole-capsid protein) to
retain an immunity level sufficiently high to resist outbreaks. The trials conducted have shown encouraging results in terms of immunity and protection (6, 7). Alternatively, one can
consider the use of recombinant viral nonstructural proteins (3ABC and 2C) to distinguish between vaccinated and infected animals
(5). This may overcome the inherent drawback of using
conventional inactivated vaccines. Recently introduced
ready-to-formulate oil adjuvants (Montanide series) have proven to
maintain immunity for a long duration (
6 to 8 months)
(1) (P. K. Patil, J. Bayry, S. P. Nair, L. D. Misra, and C. Natarajan, submitted for publication). They have even
proven to reduce contact transmission of the virus in sheep, which are
the main virus carriers (2). Thus, regular annual
vaccination by utilizing these new adjuvants as well as concentrated
antigen maintained at international FMD banks would be another
alternative. The maintenance of an increased level of immunity would
prevent the buildup of high levels of circulating virus in populations
close to disease foci, thus allowing the authorities more time to deal
with slaughter and disinfection of contaminated areas. Therefore, we
favor the use of one of these alternative approaches along with a
slaughtering policy in disease-free countries.
 |
FOOTNOTES |
*
Phone: 33 1 43 95 95 89
Fax: 33 1 45 45 90 59
E-mail: srini.kaveri{at}brs.ap-hop-paris.fr
 |
REFERENCES |
| 1.
|
Barnett, P. V.,
L. Pullen,
L. Williams, and T. R. Doel.
1996.
International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants.
Vaccine
14:1187-1198[CrossRef][Medline].
|
| 2.
|
Cox, S. J.,
P. V. Barnett,
P. Dani, and J. S. Salt.
1999.
Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission.
Vaccine
17:1858-1868[CrossRef][Medline].
|
| 3.
|
Ferguson, N. M.,
C. A. Donnelly, and R. M. Anderson.
2001.
The foot-and-mouth epidemic in Great Britain: pattern of spread and impact of interventions.
Science
292:1155-1160[Abstract/Free Full Text].
|
| 4.
|
Kitching, R. P.
1998.
A recent history of foot-and-mouth disease.
J. Comp. Pathol.
118:89-108[Medline].
|
| 5.
|
Mackay, D. K.,
M. A. Forsyth,
P. R. Davies,
A. Berlinzani,
G. J. Belsham,
M. Flint, and M. D. Ryan.
1998.
Differentiating infection from vaccination in foot-and-mouth disease using a panel of recombinant, non-structural proteins in ELISA.
Vaccine
16:446-459[CrossRef][Medline].
|
| 6.
|
Morgan, D. O., and D. M. Moore.
1990.
Protection of cattle and swine against foot-and-mouth disease using biosynthetic peptide vaccines.
Am. J. Vet. Res.
51:40-45[Medline].
|
| 7.
|
Ward, G.,
E. Rieder, and P. W. Mason.
1997.
Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine.
J. Virol.
71:7442-7447[Abstract].
|
| 8.
|
Woolhouse, M.,
M. Chase-Topping,
D. Haydon,
J. Friar,
L. Matthews,
G. Hughes,
D. Shaw,
J. Wilesmith,
A. Donaldson,
S. Cornel,
M. Keeling, and Bryan Grenfell.
2001.
Foot-and-mouth disease under control in the UK.
Nature
411:258-259[Medline].
|
| | | | |
Jagadeesh Bayry*
Srini V. Kaveri
INSERM U 430 Hopital Broussais 96, rue Didot 75014 Paris, France
|
Journal of Clinical Microbiology, October 2001, p. 3808-3808, Vol. 39, No. 10
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3808.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.